{"id":390643,"date":"2018-06-19T00:00:00","date_gmt":"2018-06-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreop0004-2018-biopharma-diabetic-macular-edema-diabetic-retinopathy-access-and-reimbursement-us-2018\/"},"modified":"2026-03-31T10:48:17","modified_gmt":"2026-03-31T10:48:17","slug":"acreop0004-2018-biopharma-diabetic-macular-edema-diabetic-retinopathy-access-and-reimbursement-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreop0004-2018-biopharma-diabetic-macular-edema-diabetic-retinopathy-access-and-reimbursement-us-2018\/","title":{"rendered":"Diabetic Macular Edema \/ Diabetic Retinopathy  | Access and Reimbursement | US | 2018"},"content":{"rendered":"<p>Vascular endothelial growth factor (VEGF) inhibitors\u2014approved agents Eylea (Regeneron) and Lucentis (Roche\/Genentech), and off-label Avastin (Roche\/Genentech)\u2014are the treatment mainstays for diabetic macular edema (DME). Allergan\u2019s Ozurdex and Alimera Sciences\u2019 Iluvien, two long-acting corticosteroid implants, are also used to treat DME. The market heated up in April 2017 when the label of Lucentis 0.3 mg was expanded to treat patients with diabetic retinopathy (DR) without DME. Factoring in the anticipated approval of Eylea for nonproliferative DR patients without DME in the United States, as well as the expected availability of biosimilars of Lucentis 0.5 mg and Eylea and emerging therapies for DME, this report delivers actionable insights to help companies best position their DME\/DR products to succeed in the U.S. access and reimbursement environment.<\/p>\n<p><strong>Questions\u00a0Answered<\/strong><\/p>\n<ul>\n<li>Does coverage of therapies for DME differ on MCOs\u2019 largest Medicare Advantage and commercial insurance plans? How do various cost-control measures impact prescribing of current therapies for DME?<\/li>\n<li>How do pharmacoeconomic\/health economic outcomes data impact formulary decision-making for drugs for DME?<\/li>\n<li>Do physicians expect to prescribe the emerging therapies abicipar pegol (Allergan), Luminate (Allegro Ophthalmics), and RG-7716 (Roche) to their DME patients? What factors would influence preferred coverage of these agents on the MCOs\u2019 largest risk-based commercial plans?<\/li>\n<li>How is the expected availability of biosimilars of Lucentis 0.5 mg and Eylea likely to impact access to and reimbursement of the originator branded therapies for DME?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Access &#038; Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.<\/p>\n<p><strong>Markets covered:\u00a0<\/strong>United States<\/p>\n<p><strong>Primary research:<\/strong><\/p>\n<ul>\n<li>Survey of 104\u00a0ophthalmologists\/retinal specialists in the United States.<\/li>\n<li>Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs\/MDs).<\/li>\n<\/ul>\n<p><strong>Key companies:\u00a0<\/strong>Roche\/Genentech, Regeneron, Alimera Sciences,\u00a0Allergan, Allegro Ophthalmics<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Avastin, Eylea, Lucentis, Iluvien, Ozurdex, RG-7716, Luminate, abicipar pegol<\/p>\n<p><strong>Content highlights:<\/strong><\/p>\n<ul>\n<li>Reimbursement and contracting.<\/li>\n<li>Access and prescribing.<\/li>\n<li>Special topics.<\/li>\n<li>Opportunities and challenges for emerging therapies.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390643","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-macular-edema","biopharma-therapy-areas-diabetic-retinopathy","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390643\/revisions"}],"predecessor-version":[{"id":576727,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390643\/revisions\/576727"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}